FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2945954186> ?p ?o ?g. }

• W2945954186 abstract "SUMMARY INTRODUCTION Interferons have been used to treat basal cell carcinoma with positive results. Cuba’s Genetic Engineering and Biotechnology Center developed HeberPAG, a combined formulation of interferons alpha-2b and gamma, for treatment of basal cell carcinoma of any size, subtype and location. OBJECTIVE Evaluate the safety and effectiveness of using Heber-PAG in primary care to treat basal cell carcinomas. METHODS A descriptive observational study was conducted of basal cell carcinoma treated with HeberPAG. The sample comprised 21 tumors in 19 patients who met selection criteria. The dose was 3.5 million international units of antiviral activity administered by perilesional infiltration 3 times a week for 3 weeks. Clinical monitoring and laboratory testing of patients was conducted before treatment initiation and at 4, 8, 16 and 52 weeks. Variables recorded were: age, sex, skin phototype, clinical and histologic type, clinical response to treatment, changes in tumor diameters and adverse events. Four response categories were included: complete response, partial response, stable disease and progressive disease. Data were recorded in medical dossiers. Microsoft Excel and SAS were used for data management and calculation of measures of frequency, central tendency and dispersion. RESULTS Of 19 patients studied, 63% were male, and 63% aged 61–80 years. At 16 weeks, there was an objective response in 76% of tumors (8 complete and 8 partial responses). Fewer objective responses were seen in rodent ulcer, advanced invasive and sclerosing clinical types and in the sclerodermiform histologic type. Mean sum of diameters decreased from 36.9 mm (SD 4.1 mm) to 10.3 mm (SD 18.3 mm). One-year recurrence was 10%. The most common adverse reaction was flu-like syndrome, consisting of fever, malaise, joint pain and muscle pain. CONCLUSIONS Basal cell carcinoma can be successfully treated in primary care settings with a combination of interferons alpha-2b and gamma administered by trained personnel. At the dose employed in this study, the formulation produces a favorable response in basal cell carcinomas of low clinical and histologic risk, and is well tolerated, with only mild side effects. CONTRIBUTION OF THIS RESEARCH This study demonstrates the feasiblity of treating basal cell carcinoma in primary care settings with a combined formulation of interferons alpha-2b and gamma, enabling management in primary care of a cancer usually treated in hospital." @default.
• W2945954186 created "2019-05-29" @default.
• W2945954186 creator A5067727981 @default.
• W2945954186 creator A5073086953 @default.
• W2945954186 creator A5089541971 @default.
• W2945954186 date "2018-01-01" @default.
• W2945954186 modified "2023-09-27" @default.
• W2945954186 title "Treatment of Basal Cell Carcinoma with Interferons Alpha-2b and Gamma in Primary Care" @default.
• W2945954186 doi "https://doi.org/10.37757/mr2018.v20.n1.4" @default.
• W2945954186 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34229416" @default.
• W2945954186 hasPublicationYear "2018" @default.
• W2945954186 type Work @default.
• W2945954186 sameAs 2945954186 @default.
• W2945954186 citedByCount "0" @default.
• W2945954186 crossrefType "journal-article" @default.
• W2945954186 hasAuthorship W2945954186A5067727981 @default.
• W2945954186 hasAuthorship W2945954186A5073086953 @default.
• W2945954186 hasAuthorship W2945954186A5089541971 @default.
• W2945954186 hasBestOaLocation W29459541861 @default.
• W2945954186 hasConcept C121608353 @default.
• W2945954186 hasConcept C126322002 @default.
• W2945954186 hasConcept C141071460 @default.
• W2945954186 hasConcept C195910791 @default.
• W2945954186 hasConcept C197934379 @default.
• W2945954186 hasConcept C23131810 @default.
• W2945954186 hasConcept C2777546739 @default.
• W2945954186 hasConcept C2777789703 @default.
• W2945954186 hasConcept C2778024521 @default.
• W2945954186 hasConcept C2778804307 @default.
• W2945954186 hasConcept C2779306644 @default.
• W2945954186 hasConcept C3019992690 @default.
• W2945954186 hasConcept C71924100 @default.
• W2945954186 hasConcept C90924648 @default.
• W2945954186 hasConceptScore W2945954186C121608353 @default.
• W2945954186 hasConceptScore W2945954186C126322002 @default.
• W2945954186 hasConceptScore W2945954186C141071460 @default.
• W2945954186 hasConceptScore W2945954186C195910791 @default.
• W2945954186 hasConceptScore W2945954186C197934379 @default.
• W2945954186 hasConceptScore W2945954186C23131810 @default.
• W2945954186 hasConceptScore W2945954186C2777546739 @default.
• W2945954186 hasConceptScore W2945954186C2777789703 @default.
• W2945954186 hasConceptScore W2945954186C2778024521 @default.
• W2945954186 hasConceptScore W2945954186C2778804307 @default.
• W2945954186 hasConceptScore W2945954186C2779306644 @default.
• W2945954186 hasConceptScore W2945954186C3019992690 @default.
• W2945954186 hasConceptScore W2945954186C71924100 @default.
• W2945954186 hasConceptScore W2945954186C90924648 @default.
• W2945954186 hasLocation W29459541861 @default.
• W2945954186 hasOpenAccess W2945954186 @default.
• W2945954186 hasPrimaryLocation W29459541861 @default.
• W2945954186 hasRelatedWork W130882478 @default.
• W2945954186 hasRelatedWork W1893282120 @default.
• W2945954186 hasRelatedWork W1970434391 @default.
• W2945954186 hasRelatedWork W1981015634 @default.
• W2945954186 hasRelatedWork W2003534255 @default.
• W2945954186 hasRelatedWork W2045308241 @default.
• W2945954186 hasRelatedWork W2050741039 @default.
• W2945954186 hasRelatedWork W2063022515 @default.
• W2945954186 hasRelatedWork W2066845644 @default.
• W2945954186 hasRelatedWork W2396858895 @default.
• W2945954186 hasRelatedWork W2399147871 @default.
• W2945954186 hasRelatedWork W2411010427 @default.
• W2945954186 hasRelatedWork W2411525988 @default.
• W2945954186 hasRelatedWork W2411631076 @default.
• W2945954186 hasRelatedWork W2415683174 @default.
• W2945954186 hasRelatedWork W2428596843 @default.
• W2945954186 hasRelatedWork W2463178207 @default.
• W2945954186 hasRelatedWork W2465056471 @default.
• W2945954186 hasRelatedWork W94629933 @default.
• W2945954186 hasRelatedWork W2417503159 @default.
• W2945954186 isParatext "false" @default.
• W2945954186 isRetracted "false" @default.
• W2945954186 magId "2945954186" @default.
• W2945954186 workType "article" @default.